E2F3

Across TCGA pan-cancer cohorts, E2F3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of E2F3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where E2F3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types E2F3 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where E2F3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in E2F3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.501	<.001	8	view →
LSCC	Male	All	+0.375	<.001	4	view →
PDAC	All	All	−0.799	.040	2	view →
CCRCC	Female	All	−0.305	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

E2F3–LUAD

Open the LUAD breakdown →